At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 45 enrolled
Drug / intervention
Caffeine +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as "Inje Cocktail" in Healthy Subjects
In Brief
A Phase 4 clinical trial evaluating Caffeine, Losartan, and 4 other interventions for Transplant Rejection. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTransplant Rejection
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionApr 2013
TodayJul 2026
First PostedJan 11, 2013
Enrollment StartJan 1, 2013
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.5 years ago
Interventions
Caffeinedrug
Losartandrug
Omeprazoledrug
Dextromethorphandrug
Midazolamdrug
Belataceptbiological